{"filing":{"accession_number":"0001104659-26-095908","cik":"0001133869","ticker":"CAPR","company_name":"CAPRICOR THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"capr-20260813x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813x8k.htm"},"events":[{"id":27574,"run_id":25142,"accession_number":"0001104659-26-095908","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, furnished as a press release exhibit (EX-99.1) under Item 2.02. The filing discloses financial results including revenue ($0), operating expenses ($42.9M for Q2), and net loss ($40.7M or $0.70 per share), along with cash position ($237.9M) and financial outlook. While the press release also includes material regulatory and clinical updates regarding Deramiocel's FDA review and HOPE-3 results, the Item 2.02 classification centers on the financial results disclosure itself.","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29159,"accession_number":"0001104659-26-095908","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, furnished as a press release exhibit (EX-99.1) under Item 2.02. The filing discloses financial results including revenue ($0), operating expenses ($42.9M for Q2), and net loss ($40.7M or $0.70 per share), along with cash position ($237.9M) and financial outlook. While the press release also includes material regulatory and clinical updates regarding Deramiocel's FDA review and HOPE-3 results, the Item 2.02 classification centers on the financial results disclosure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:00:43.520263+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29159,"accession_number":"0001104659-26-095908","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, furnished as a press release exhibit (EX-99.1) under Item 2.02. The filing discloses financial results including revenue ($0), operating expenses ($42.9M for Q2), and net loss ($40.7M or $0.70 per share), along with cash position ($237.9M) and financial outlook. While the press release also includes material regulatory and clinical updates regarding Deramiocel's FDA review and HOPE-3 results, the Item 2.02 classification centers on the financial results disclosure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:00:43.520263+00:00","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-08-13"}]}